Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort

HIV Clinical Trials

Volumn 15, Issue 4, 2014, Pages 151-160

  Di Biagio, Antonio ^a   Nicolini, Laura ^a   Lorenzini, Patrizia ^b   Puoti, Massimo ^c   Antinori, Andrea ^b   Cozzi Lepri, Alessandro ^d   Gori, Andrea ^e   Vecchiet, Jacopo ^f   Mussini, Cristina ^g   Andreoni, Massimo ^h   Viscoli, Claudio ^a   D'Arminio Monforte, Antonella ⁱ  

^a UNIVERSITY OF GENOA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Ospedale Azienda Ospedaliera San Gerardo   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

darunavir; hepatitis C virus; hepatotoxicity; HIV; liver enzyme elevations; ritonavir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DARUNAVIR PLUS RITONAVIR; HEPATITIS B SURFACE ANTIGEN; LIVER ENZYME; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTRANSAMINASEMIA; INTRAVENOUS DRUG ABUSE; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; PRIORITY JOURNAL; SEXUAL INTERCOURSE; VIRUS LOAD;

DARUNAVIR; HEPATITIS C VIRUS; HEPATOTOXICITY; HIV; LIVER ENZYME ELEVATIONS; RITONAVIR;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIVER; MALE; MIDDLE AGED; RITONAVIR; SULFONAMIDES;

EID: 84906684023     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1504-151     Document Type: Article

References (38)

1. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother. 2006;57:815-818.
2. Nunez M, Lana R, Mendoza JL, Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defi c Syndr. 2001;27:426-431.
3. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. Drug Saf. 2005;28:53-66.
4. Puoti M, Torti C, Ripamonti D, et al, for the HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: Incidence, liver histology, and outcome. J Acquir Immune Defic Syndr. 2003;32:259-326.
5. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS. 1999;13:F115-F121.
6. Saves M, Vandentorren S, Daucourt V, et al, for the NN Study Team. Comparison of fi rst-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised openlabel trial, the 2NN Study. Lancet. 2004;363:1253-1263.
7. Sulkowski M. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004;38:S90-S97.
8. Meraviglia P, Schiavini M, Castagna A, et al. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: Evaluation of risk factors for liver enzyme elevation. HIV Med. 2004;5:334-343.
9. Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS. 2003;14:776-781.
10. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
11. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleosid reverse transcriptase inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S80-S89.
12. Cicconi P, Cozzi Lepri A, Philips A, et al. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy ? AIDS. 2007;21:599-606
13. Fontana R, Seeff L, Andrade R, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop. Hepatology. 2010; 52:730-742.
14. Sabin CA Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin Infect Dis. 2004;38(Suppl. 2):S56-64
15. Llibre JM, Imaz A, Clotet B. From TMC114 to darunavir: Five years of data on effi cacy. AIDS Rev. 2013;15:112-121.
16. Berhan A, Berhan Y. Virologic response to tipranavirritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: A metaanalysis and meta-regression of randomized controlled clinical trials. PLoS One. 2013;8:e60814.
17. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatmentnaïve, HIV-1 infected patients: 96-week analysis. AIDS. 2009;23:1679-1688.
18. Bánhegyi D, Katlama C, da Cunha CA, et al. Week 96 effi cacy, virology and safety of darunavir/ritonavir versus lopinavir/ritonavir in treatment-experienced patients in TITAN. Curr HIV Res. 2012;10:171-181.
19. Arasteh K, Yeni P, Pozniak A, et al. Effi cacy and safety of darunavir/ritonavir in treatment experienced HIV-1 patients in the POWER 1, 2 and 3 trials at week 96. Antiviral Ther. 2009;14:859-864.
20. FDA alerts doctors to Prezista's possible link to liver damage, deaths. AIDS Read. 2008,18:235.
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 2, 2013. http://www. aidsinfo.nih.gov/guidelines. Accessed March 10, 2014.
22. D'Arminio Monforte A, Pezzotti P, et al. Determinants of initiation of antiretroviral therapy (HAART) in an Italian cohort of HIV-positive patients naive from antiretrovirals (ICoNA Study). AIDS. 1998;12:99. [Database can be found at http://www.icona.org]
23. Uberti-Foppa C, De Bona A, Morsica G et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defi c Syndr. 2003;33:146-152.
24. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis. 2007;196:670-676.
25. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.
26. Sulkowski M, Thomas D, Chasson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
27. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology. 2002;35:182-189.
28. Servin-Abad L, Molina E, Baracco G, et al. Liver enzymes elevation after HAART in HIVHCV co-infection. J Viral Hepat. 2005;12:429-434.
29. Bonnet F, Lawson-Ayayi S, Tiebaut R, et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitanie Cohort, 1997-1999. Clin Infect Dis. 2002; 35:1231-1237.
30. Stone SF, Lee S, Keane NM, et al. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodefi ciency virus-HCV-coinfected patients. J Infect Dis. 2002;186:1498-1502.
31. Ofotokun I, Smithson SE, Lu C, Easley KA, Lennox JL. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci. 2007;334:334-341.
32. Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in Power 1 and 3. HIV Clin Trials. 2007;84:213-220
33. Jain MK. Drug-induced liver injury associated with HIV medications. Clin Liver Dis. 2007;11:615-639.
34. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1-13.
35. Sulkowski M, Thomas D, Chaisson R, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
36. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once daily atazanavir/ritonavir compared with twice daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96 week efficacy and safety results of the castle Study. J Acquir Immune Defi c Syndr. 2010;53:323-332.
37. Ha B, Wine B, Rodriguez-Alcantra F, Shaefer M. Hepatic safety profile of fosamprenavir-containing regimens in HIV-infected patients with or without hepatitis B or C coinfection. HIV Clin Trials. 2012;13:171-177.
38. Mikl J, Sulkowski MS, Benhamou Y, et al. Hepatic safety profile analyses of tipranavir in Phase II and III clinical trials. BMC Infect Dis. 2009;9:203.